Abstract 1502P
Background
Rectal cancer treatments have improved significantly over the past two decades, leading to higher survival rates. However, there's a growing emphasis on the long-term quality of life for survivors, including addressing sexual health needs. Our study aims to evaluate QOL, particularly sexual dysfunction, using validated tools like EORTC QLQ-C30, QLQ-CR29, and GRISS, aiming to improve care for rectal cancer patients.
Methods
Validated questionnaires (EORTC QLQ-C30, QLQ-CR29, GRISS) were completed by participants, assessing various aspects of quality of life and sexual satisfaction. Statistical analyses included tests for normality, descriptive analyses of patient characteristics, correlation analyses between questionnaire scores, and comparison of median scores using appropriate tests.
Results
The study included a total of 83 participants. Mean age of 55.95 ± 11.53, predominantly under 65 years (79.5%). A majority of patients (65.1%) had a stoma, and 78.3% underwent surgery, with 67.5% retaining sphincter function. The cohort was divided into non-metastatic (60.2%) and metastatic (39.8%) groups Significant correlations were observed between the Golombok Total Score and various subscores of the C30 scale. The fatigue subscore correlated positively with Golombok-female Total Score (r=0.331, p=0.041) and Golombok-male Total Score (r=0.370, p=0.042). Body image (p
Conclusions
This study demonstrates the profound and varied impact of rectal cancer treatment on patients' sexual health and overall quality of life, particularly affected by the presence of a stoma and metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10